Results 121 to 130 of about 24,362 (263)

Seizure relapse in new onset epilepsy: It is not always drug resistance

Epilepsia, EarlyView.
Abstract Objective Seizure recurrence in new onset epilepsy (NOE) can result from various factors. Although drug ineffectiveness is frequently investigated, other causes—such as nonadherence, inadequate treatment, nonepileptic events (e.g., functional/dissociative), or acute symptomatic seizures—also impact patient outcomes.
Cecilia Catania, Eric Menetre, Aikaterini Fitsiori, Felix Tobias Kurz, Gabriela Moreno Legast, Serge Vulliemoz, Mathieu Genoud, Pierre Mégevand, Roland Wiest, Fabienne Picard, Sandor Beniczky, Margitta Seeck   +11 more
wiley   +1 more source

Clinical validation of a patient‐friendly saliva microsampling approach to monitor perampanel levels in people with epilepsy

Epilepsia, EarlyView.
Abstract Perampanel (PER) is a third‐generation antiseizure medication (ASM) with a well‐established concentration–effect relationship. Saliva represents a non‐invasive alternative to plasma for therapeutic drug monitoring (TDM) of PER, as it reflects the free plasma fraction.
Valentina Franco, Francesca Dattrino, Michela Palmisani, Federica Tacchella, Elena Tartara, Valentina De Giorgis, Carlo Alberto Quaranta, Ludovica Pasca, Paola Rota, Emilio Russo, Andrea Romigi, Cecilie Johannessen Landmark, Guido Fedele, Cristina Tassorelli, Pierluigi Nicotera   +14 more
wiley   +1 more source

Long‐term prognosis of pharmacotherapy in newly diagnosed focal epilepsy patients and the predictive value of baseline seizure timing: A prospective cohort study

Epilepsia, EarlyView.
Abstract Objective Epilepsy is a highly heterogeneous neurological disorder with significant prognostic variability. Accurate long‐term outcome prediction remains a clinical challenge. We investigated pharmacotherapeutic prognosis and key predictors, particularly baseline seizure timing, to guide individualized treatment.
Lei Sun, Shouye Sun, Xinyue Zhang, Weihong Lin   +3 more
wiley   +1 more source

Lamotrigine-induced lupus

, 2000
A 57-year-old woman was under treatment for epilepsy with lamotrigine 2 mg/kg/d since 1996. In April 1998 she was admitted to the Rheumatology Unit for arthralgias affecting the small joints of the hands, wrists and knees, erythematosus skin rash and ...
P. Sarzi-Puttini, M. Cazzola, B. Panni, S. Muzzupappa, M. Turiel   +4 more
core   +1 more source

Add‐on treatment with vinpocetine reduces seizure frequency and improves comorbidities in patients with loss‐of‐function γ‐aminobutyric acid type A receptor variants

Epilepsia, EarlyView.
Abstract Objective The semisynthetic compound vinpocetine has gained attention as a potential precision medicine for developmental and epileptic encephalopathies caused by loss‐of‐function (LoF) variants in γ‐aminobutyric acid type A (GABAA) receptor genes. As a positive allosteric modulator of GABAA receptors, case reports suggest that vinpocetine can
Cathrine E. Gjerulfsen, Vivian W. Y. Liao, Tomasz S. Mieszczanek, Anne V. Jakobsen, Elena Gardella, Kern Olofsson, Marina Nikanorova, Allan Bayat, Sebastian Ortiz, Sarah Weckhuysen, Cecilie Johannessen Landmark, Orrin Devinsky, Mary Chebib, Philip K. Ahring, Guido Rubboli, Rikke S. Møller   +15 more
wiley   +1 more source

Effectiveness of lamotrigine in bipolar disorder in a clinical setting

, 2013
OBJECTIVE: To assess lamotrigine effectiveness in bipolar disorder (BD) patients in a clinical setting. METHOD: Open lamotrigine was naturalistically administered to outpatients at the Stanford University BD Clinic assessed with the Systematic Treatment ...
Brooks, John O., Ketter, Terence A., Culver, Jennifer L., Marsh, Wendy K., Bonner, Julie C., Nam, Jennifer Y., Champion, Laurel M., Hoblyn, Jennifer C.   +7 more
core   +1 more source

Compensatory rearrangement of parvalbumin interneuron voltage‐gated sodium channel subunits in a mouse model of Dravet syndrome

Epilepsia, EarlyView.
Abstract Heterozygous loss‐of‐function variants in the gene SCN1A, which encodes the voltage‐gated sodium channel (VGSC) pore‐forming (α) subunit NaV1.1, lead to a spectrum of neurological disease, including Dravet syndrome. NaV1.1 is prominently expressed at the proximal portion of the axon initial segment (AIS) of fast‐spiking γ‐aminobutyric ...
Ania K. Dabrowski, Ala Somarowthu, Sophie R. Liebergall, Damaris N. Lorenzo, Ethan M. Goldberg   +4 more
wiley   +1 more source

Gamma suppression correlates with thalamic stimulation therapeutic response in intractable epilepsy

Epilepsia, EarlyView.
Abstract Objective In patients with drug‐resistant epilepsy who undergo anterior nucleus of the thalamus (ANT) deep brain stimulation (DBS), efficacy is assessed months after therapy initiation and clinicians have no guidance when choosing stimulation parameters due to the lack of real‐time biomarkers.
Zachary T. Sanger, Xinbing Zhang, Thomas Lisko, Hafsa Farooqi, Steffen Ventz, Sandipan Pati, Thomas R. Henry, David P. Darrow, Michael C. Park, Theoden I. Netoff, Robert A. McGovern   +10 more
wiley   +1 more source

Efficacy, safety, and potential of extended-release lamotrigine in the treatment of epileptic patients

, 2010
Barbara Błaszczyk1,2, Stanisław J Czuczwar3,41Department of Neurology, Neuropsychiatric Hospital, Kielce, Poland; 2Faculty of Health Sciences, High School of Economics and Law, Kielce, Poland; 3Department of Pathophysiology, Medical University, Lublin ...
Barbara Błaszczyk, Stanisław J Czuczwar   +1 more
core  

Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics

, 2012
What is known and Objective: Lamotrigine metabolism may be substantially altered with concomitant administration of valproic acid and/or carbamazepine. Such alterations may require the adjustment of lamotrigine dose to ensure optimal treatment efficacy ...
Vučićević, Katarina, Prostran, Milica, Brzaković, B. B., Vezmar-Kovačević, Sandra, Martinović, Žarko J., Pokrajac, Milena, Miljković, Branislava   +6 more
core   +1 more source